Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1440-1819.2009.01953.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacokinetic Prediction of Immediate- and Extended-Release Tablets for Patients with Liver Disease Using Whole Body Physiologically-Based Pharmacokinetic Modeling for the Antipsychotic Drug Quetiapine.
AAPS PharmSciTech
December 2024
College of Pharmacy, Sunchon National University, 255 Jungang-ro, Suncheon-si, 57922, Jeollanam-do, Republic of Korea.
Although quetiapine metabolism occurs extensively in the liver and careful dosing is recommended in patients with liver disease, there has been a paucity of pharmacometric studies to adjust the clinical dose of quetiapine according to liver-disease severity. This study aimed to establish a whole-body, physiologically-based pharmacokinetic (WB-PBPK) model to explain interindividual variability in quetiapine PK and quantitatively predict PK in patients with liver disease. The developed WB-PBPK model well described the PK characteristics of different quetiapine regimens in healthy populations.
View Article and Find Full Text PDFCorticosteroid-induced psychosis is rare and less reported in children compared to adults. However, psychosis is considered a severe adverse effect of corticosteroids in pediatric nephrotic syndrome. Steroid-induced psychosis is dose-dependent and should be treated by tapering the dose of steroids and usually initiating an atypical antipsychotic.
View Article and Find Full Text PDFIntroduction: Delirium is a common and serious neurological complication in intensive care units (ICUs), often leading to poor patient outcomes and increased mortality. This study aimed to compare the incidence of delirium in ICU patients with COVID-19 to those with other respiratory infections in a private hospital in Costa Rica. Additionally, it evaluated the prevalence, severity, duration, and treatment of delirium in these critically ill patients.
View Article and Find Full Text PDFInhibition of HCN1 currents by norquetiapine, an active metabolite of the atypical anti-psychotic drug quetiapine.
Front Pharmacol
October 2024
Département de Pharmacologie et Physiologie, Université de Montréal, Montréal, QC, Canada.
Article Synopsis
- Quetiapine is an atypical antipsychotic used to treat schizophrenia and depression, and its effect may be linked to inhibiting HCN channels.
- Research showed that norquetiapine, a major active metabolite of quetiapine, selectively inhibits HCN1 channels, altering their activation and slowing their function without affecting closing kinetics.
- These findings suggest that HCN channels are important targets for norquetiapine, providing insight into how quetiapine works therapeutically and opening doors for new drug development targeting HCN channels.
Effects of dopamine receptor antagonists and radiation on mouse neural stem/progenitor cells.
Radiother Oncol
December 2024
Department of Radiation Oncology, David Geffen School of Medicine at UCLA, United States; Jonsson Comprehensive Cancer Center at UCLA, United States; Department of Neurosurgery, David Geffen School of Medicine at UCLA, United States.
Background: Dopamine receptor antagonists have recently been identified as potential anti-cancer agents in combination with radiation, and a first drug of this class is in clinical trials against pediatric glioma. Radiotherapy causes cognitive impairment primarily by eliminating neural stem/progenitor cells and subsequent loss of neurogenesis, along with inducing inflammation, vascular damage, and synaptic alterations. Here, we tested the combined effects of dopamine receptor antagonists and radiation on neural stem/progenitor cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!